US Head of Finance

Alfasigma is a privately held global healthcare company founded over 75 years ago in Italy, where it remains headquartered today in Bologna and Milan. The Group operates in over 100 markets spanning Europe, North and South America, Asia, and Africa. Over three years ago, the Company embarked on a transformative journey to become a truly global innovative healthcare company with a leading focus in Gastrointestinal (GI) health. The Group has experienced remarkable growth, nearly doubling revenues, expanding geographically, and integrating several key acquisitions. Alfasigma has also evolved their portfolio, expanded into rare and specialty segments, and strengthened their pipeline and people capabilities.

This is just the beginning of a bold new chapter in Alfasigma's history. The Group is committed to advancing innovation and leveraging their deep expertise to provide better health and a better quality of life for patients and consumers worldwide, expanding their reach across diverse markets.

Alfasigma employs approximately 4,000 people dedicated to research, development, production, and distribution of medicinal products, contributing to its mission to provide better health and a better quality of life for patients, caregivers, and healthcare providers. It focuses on three main therapeutic areas: Gastroenterology, Vascular, and Rheumatology. Its portfolio spans from primary care to specialty care, rare disease medications, and consumer health products, including medical foods and nutraceuticals.

GSK and Alfasigma Agreement

Alfasigma has significant experience in developing and commercializing therapies for serious liver diseases, including PBC, and has products in more than 100 markets worldwide. GSK plc and Alphasigma S.p.A. recently announced a license agreement* under which Alfasigma will acquire worldwide exclusive rights to develop, manufacture and commercialize linerixibat, an ileal bile acid transporter (IBAT) inhibitor developed for cholestatic pruritus in primary biliary cholangitis (PBC).

Linerixibat has been granted Orphan Drug Designation in the US, EU and Japan, and priority review in China, for the treatment of cholestatic pruritus in patients with PBC. Linerixibat now has received market approval in the U.S., and marketing applications are under regulatory review in the UK, EU, China and Canada, based on positive data from the GLISTEN phase III trial.

About linerixibat (GSK2330672)

Linerixibat is an IBAT inhibitor, a targeted oral agent with potential to treat cholestatic pruritus (itch) associated with the rare autoimmune liver disease PBC. By inhibiting bile acid re-uptake, linerixibat reduces multiple mediators of pruritus in circulation.

*the transaction is subject to appropriate Federal Trade Commission approvals in the United States and a successful outcome is expected imminently.

FINANCIAL AND OPERATIONAL HIGHLIGHTS

• Alfasigma is a privately held pharmaceutical company headquartered in Italy.
• Alfasigma reported full‑year 2025 revenues of approximately €1.8 billion.
• U.S. revenue growth is expected to accelerate with upcoming rare disease launches.
• Alfasigma reports a strong balance sheet and financial flexibility, supported by disciplined cost management and adjusted EBITDA of approximately €350 million in 2025, enabling significant ongoing investment in U.S. launch and portfolio expansion activities.

CULTURE

Passion for Innovation

We foster a passion for innovation because we care for our patients, our people and our communities.

To address and solve patients’ needs we are driven to dream big, imagine the impossible and innovate to create impactful and life-improving solutions.

It requires curiosity, creativity, and an inclusive culture, where everyone feels valued and where diverse perspectives fuel our capacity to innovate thus creating better ideas.

Think Big, Act Small

We think big and act small with high integrity every day to move fast and create impact.

We set ambitious goals and focus on the big ideas that are most impactful for our patients and business. We stay humble and act small in the sense that we operate with the energy, flexibility and speed of a start-up because our patients can’t wait. We live by high ethical standards, deliver results with tenacity and a strong sense of urgency, while we keep our eye on the destination.

Learn to Dare

We learn more to dare more, in order to grow and create new opportunities.

We are driven by curiosity and a desire to improve ourselves. When we continue to learn, deepen our understanding, and build new skills and capabilities, we gain confidence and create new opportunities and push our boundaries. We must have the courage to take risks and learn from our mistakes and help each other grow and develop.

Teams Build the Future

We are a company where high performance teams build the future and grow together, fueled by personal accountability.

We have a unique opportunity to build and shape the future of Alfasigma. What we are trying to do cannot be done alone. The best outcomes come from a balance of personal accountability and ownership, teamwork and collaboration, built on mutual respect and care, both internally and externally. By aligning around common goals, trusting and empowering each other, we can create the future as one united Alfasigma.

ALFASIGMA US

As Alfasigma USA continues its strong growth trajectory, we are seeking a dynamic US Head of Finance to join the Alfasigma USA Leadership Team. This executive will oversee financial leadership of our RX/Rare and Specialty, US Nutrition businesses and global operating units based in the US, playing a pivotal role in shaping the future of our US organization.

Based in New Jersey, the US organization consists of an integrated U.S. commercial and medical affairs organization of approximately 120 associates in the rare disease business, an US Nutrition business of approximately 180 associates, a Global R and D organization of approximately 60 associates and a G&A function comprised of HR, Finance and IT of 30 associates.

SCOPE OF THE ROLE

Reporting directly to the US President, the US Head of Finance will serve as a key strategic advisor and business partner. This leader will drive performance across both business units, develop and execute financial plans, and maintain a sharp focus on revenue optimization, P&L management and Net Working Capital optimization. The role also ensures strong financial operational discipline across accounting, FP&A, and external audit collaboration.

LOCATION

This role is based in Morristown, New Jersey, with an expectation of on‑site presence four days per week; candidates in the NY/NJ/Northeast region are preferred, with relocation support available and periodic international travel required.

Key Responsibilities

• Build and drive structures and processes that deliver timely, detailed insights into revenue forecasts, participate in pricing and access decisions, dynamically allocate expenses and working capital to inform and guide the financial health of the US operations.
• Lead financial and business planning processes including resource allocation decisions, responsible for delivering financial forecasts and plans in accordance with local and global financial reporting and planning processes.
• Drive and manage appropriate financial performance management cycles and reviews for US operations.
• Lead financial and business analysis discussions, offering recommendations on projected financial outcomes for investment opportunities, including mergers, acquisitions, product in‑ or out‑licensing, and new technology licensing or acquisition.
• Accountable for delivering timely and accurate management and statutory financial statements for global consolidation and US statutory reporting. Ensure full compliance with all US and international accounting and tax regulations.
• Develop and maintain compliant financial operations to support periodic audits, reviews, and related activities conducted by external auditors and internal auditing. Establish and enforce robust internal controls to ensure proper authorization, documentation, and recording of transactions in accordance with company policy and accounting standards.
• Safeguard company assets through rigorous analysis of material investment decisions, disbursements, internal controls, and periodic reviews.
• Analyze and manage cash flow requirements—including investments, expenses, and working capital—to guide decision‑making across the organization.
• Lead, staff, develop and engage the members of the US Finance team. Drive engagement with the global finance community.

Who You Are

• BS/BA in a related field; MBA strongly preferred.
• Minimum 15 years of business experience, with prior experience in pharmaceutical or biotech.
• Experience launching a new product is preferred.
• Familiarity with market access, reimbursement, and pricing for therapeutic products, ideally within rare disease expertise.
• A seasoned people leader who understands individual and group dynamics and thrives in a fast‑growth US market within a global organization.
• Broad exposure to a wide spectrum of financial disciplines and current industry practices.

Strong interpersonal skills with the ability to build relationships and influence at all levels of the organization.